Rezipres FDA Approval History
Last updated by Judith Stewart, BPharm on June 15, 2021.
FDA Approved: Yes (First approved June 14, 2021)
Brand name: Rezipres
Generic name: ephedrine hydrochloride
Dosage form: Injection
Company: Eton Pharmaceuticals, Inc.
Treatment for: Hypotension
Rezipres (ephedrine hydrochloride) is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
- Rezipres is a sulfite-free ephedrine formulation containing ephedrine hydrochloride.
- Rezipres is administered intravenously as a bolus injection.
- Common adverse reactions include nausea, vomiting, and tachycardia.
Development timeline for Rezipres
| Date | Article |
|---|---|
| Jun 15, 2021 | Approval FDA Approves Rezipres (ephedrine hydrochloride injection) for Hypotension During Anesthesia |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
